About Ionis Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.ionis.com/
Frequently Asked Questions
What is the 52-week range for IONS?
The 52-week high is $86.74 and the 52-week low is $43.0065.
What is the P/E ratio for IONS?
The P/E ratio data is currently unavailable.
What is the dividend yield for IONS?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -110.92%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -64.66%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 26.20.
Analyst Recommendation Trends
Wall Street analyst consensus for IONS over the last few months:
Latest IONS News
Cathie Wood Makes $64 Million Bet on Two Stocks
The latest trades reveal where Wood sees opportunity
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
RNA therapeutics are gaining momentum as Alnylam, Ionis, Wave Life Sciences and Arcturus advance innovative treatments targeting a range of diseases.
Alnylam Pharmaceuticals: More Than Meets The Eye After CARDIO-TTRansform
Alnylam Pharmaceuticals, Inc. is down on ATTR-CM fears. TRITON-CM could still succeed, downside is buffered, and shares look undervalued. Click for an ALNY update.
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide
Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $100 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $100 price target.
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.
Roche, Ionis RNA drug scores in kidney disease study
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, Roche’s Chief Medical Officer and Head of Glo
Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
CARLSBAD, Calif., September 23, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and partner Roche today announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with primary IgA nephropathy (IgAN). The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful improvements in proteinuria reduction, compared to placebo at 37 weeks, as measured by 24-hour urine prote
Ionis Pharmaceuticals And Partner Roche Said Prespecified Interim Results From Phase 3 IMAgINATION Study Of Sefaxersen For Primary IgA Nephropathy Met Its Primary Endpoint Of Statistically Significant And Clinically Meaningful Improvements In Proteinuria Reduction Vs. Placebo At 37 Weeks
– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential –– IgAN is a progressive kidney disease that is
Ionis to Seek Expedited FDA Review for ALS Drug
Ionis Pharmaceuticals and Otsuka Pharmaceutical report positive Phase 3 data for ulefnersen, an investigational RNA-targeted drug for ALS.
Ionis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALS
CARLSBAD, Calif., September 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Otsuka Pharmaceutical Development & Commercialization, Inc., today announced positive topline results from the Phase 3 FUSION trial evaluating ulefnersen, an investigational RNA-targeted medicine, in people living with amyotrophic lateral sclerosis (ALS) caused by mutations in the fused in sarcoma (FUS) gene, also known as FUS-ALS. The study met its primary endpoint, with ulefnersen demonstrating a statistically
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets
Cathie Wood’s ARKG bought Ionis, Beam, Veracyte and Scribe Therapeutics. Here are the biotech ETFs that also hold her latest bets.
JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
Cathie Wood Makes a Big AI Bet and Cuts Bitcoin Exposure
Ark Invest added nearly $25 million of CoreWeave as it trimmed several major AI and technology holdings
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Shares of Ionis are down more than 40% so far this year.
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two
Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?
Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events despite sharply lowering Lp(a) levels. The pelacarsen setback comes after a sharp reset in sentiment. Ionis Pharmaceuticals has posted a 7-day share price return of negative 15.99% and a 30-day share price return of negative 21.59%. Despite this, the company still has a 5-year total shareholder return of 25.67%,...
Can AstraZeneca's Broad Pipeline Offset Recent Setbacks?
AZN's pipeline setbacks weigh on its stock, but a deep late-stage pipeline and 20+ expected readouts offer key catalysts.
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]
Amneal (AMRX) Surges 8.6%: Is This an Indication of Further Gains?
Amneal (AMRX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Novartis Suffers Another Setback After Two High-Profile Surprises Hammered Shares
Novartis added another failure to its docket Wednesday, dropping an experimental treatment for the muscle-wasting disease.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Morgan Stanley 24th Annual Global Healthcare Conference September 16, 2026 7:45 AM EDTCompany ParticipantsBrett Monia -...
Baron Health Care Fund Q2 2026 Portfolio Activity
During the quarter, we added 8 new positions and exited 6 positions, bringing the number of positions in the Fund to 43.
PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
Oligonucleotide Therapeutics Market Outlook 2026-2035 - Featuring Profiles of Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics
Oligonucleotide Therapeutics Expand Beyond Rare Diseases as RNA Innovation, Targeted Delivery and Patient-Friendly Dosing Accelerate AdoptionDublin, Sept. 15, 2026 (GLOBE NEWSWIRE) -- "Oligonucleotide Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026-2035" has been added to ResearchAndMarkets.com's offering. Global Oligonucleotide Therapeutics Market to Reach USD 72.1 Billion by 2035 at a 23.4% CAGR The global oligonucleotide therapeutics market was valu
Guggenheim Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $80
Guggenheim analyst Debjit Chattopadhyay maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $89 to $80.
Ionis Has Its First Neurology Launch, But Can Zanvastro Justify Its $285,000 Price?
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) has turned decades of RNA research into its first independently launched neurology medicine. The FDA-approved Zanvastro, chemically known as zilganersen, for adults and children with Alexander disease, has taken the lead as the first approved disease-modifying treatment for the rare neurological disorder. Ionis has set a price of $285,000 per dose […]
BioCryst Pharmaceuticals: Why The Selloff Could Be An Opportunity
BioCryst Pharmaceuticals, Inc. stock update: Orladeyo Q2 revenue rose 6.7%, debt fell, and navenibart adds HAE upside. Click for more on BCRX.
BofA Sees Limited Damage from Novartis (NVS)’ Pelacarsen Miss While Citi Looks Towards Ionis (IONS)
Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in cardiovascular events in the Phase 3 Lp(a)HORIZON study. Bank of America does not believe the result breaks the Novartis (NYSE:NVS) investment thesis. The firm estimates that the failed study creates […]
Royalty Pharma (RPRX): Can Downside Protection Offset Pelacarsen’s Phase 3 Failure?
Royalty Pharma plc (NASDAQ:RPRX) disclosed that pelacarsen failed the Phase 3 Lp(a)HORIZON cardiovascular-outcomes trial conducted by Novartis AG (NYSE:NVS). The randomized, double-blind study enrolled 8,323 patients with elevated lipoprotein(a), or Lp(a), and established cardiovascular disease. Pelacarsen lowered Lp(a), but the study did not meet its primary endpoint of reducing cardiovascular events compared with placebo in […]
Ionis Pharmaceuticals, Inc. (IONS) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Wells Fargo 21st Annual Healthcare Conference September 10, 2026 8:45 AM EDTCompany ParticipantsBrett Monia - Founder,...
Cathie Wood Is Loading Up on Ionis Pharmaceuticals (IONS) Stock. Here's the Bet She's Making.
Ionis Pharmaceuticals is promising in multiple ways -- but it's not dirt cheap or without risks.
Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
NVS' del-desiran fails the HARBOR study's primary endpoint, adding to recent pipeline setbacks as investors await next steps.
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Barclays Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $85
Barclays analyst Eliana Merle maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $90 to $85.
How Novartis' Double-Stacked Failures Reverberated Through Biopharma
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday, leading to a widespread drop.
Novartis Stock Tanks Following Third Major Pipeline Setback
Following two trial misses and a third clinical setback, analysts fear Novartis may miss its 2030 growth targets without further acquisitions.
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.
Morgan Stanley Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $104
Morgan Stanley analyst Michael Ulz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $110 to $104.
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Amgen (AMGN) drops after Novartisâ pelacarsen Phase 3 miss, pressuring olpasiranâs thesis amid patent cliffs. Click here to read my most recent analysis.
Novartis pelacarsen Lp(a) trial fails, raising doubts for Amgen, Lilly
Pelacarsen lowered Lp(a) levels in more than 8,000 patients but did not reduce the risk of heart attacks, strokes, or cardiovascular death
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
On Tuesday, Novartis AG (NYSE:NVS) stock witnessed one of the sharpest single-day declines for the company in recent history. Phase 3 HARBOR Trial Misses Primary Endpoint On Tuesday, the company shared data from the global Phase 3 HARBOR study evaluating del-desiran for myotonic dystrophy type 1 (DM1). The study did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time (vHOT), a novel measure of hand myotonia. Read Also: A Wall St
Ionis Pharmaceuticals Shares Fall After Pelacarsen Phase 3 Trial Misses Primary Endpoint
Ionis Pharmaceuticals (NASDAQ:IONS) shares fell 13. 1% to $50.
Why Is Eli Lilly Stock Falling Tuesday?
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed.
Goldman Sachs Maintains Neutral on Ionis Pharmaceuticals, Lowers Price Target to $56
Goldman Sachs analyst Salveen Richter maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Neutral and lowers the price target from $69 to $56.
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $54
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $61 to $54.
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures fell as Novartis plunged 12.7% after pelacarsen’s Phase III trial missed its endpoint; other biotech stocks also declined.
Canaccord Genuity Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $85
Canaccord Genuity analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $95 to $85.
HC Wainwright & Co. Maintains Buy on Ionis Pharmaceuticals, Lowers Price Target to $100
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and lowers the price target from $115 to $100.
Market-Moving News for September 8th
NVS: -13% | Novartis shares are trading lower after the company announced the pelacarsen phase III Lp(a)HORIZON trial did not meet its primary endpoint. IONS: -13% | Ionis Pharmaceuticals shares are trading lower amid
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease - Slideshow
2026-09-07. The following slide deck was published by Ionis Pharmaceuticals, Inc.
Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down
Novartis' pelacarsen study failed to cut cardiovascular events, clouding prospects for the drug and highlighting portfolio challenges.
Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal
AMGN shares fall as NVS' pelacarsen setback casts investor concern over whether olpasiran can deliver positive phase III outcome data.
Novartis, Ionis drug failure spurs questions about an emerging class of heart medicines
Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a surprise result with important implications for cardiovascular drug research.
NVS, IONS, AMGN Stocks Drop After-Hours — What’s Driving The Selloff?
Novartis said on Friday that its late-stage trial of pelacarsen failed to reduce the risk of cardiovascular events.
Novartis, Ionis Tumble On Surprise Flop For Heart Drug
Novartis said late Friday its Ionis-partnered Lp(a) blocker failed in testing. The results sent Novartis and Ionis stocks tumbling.
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)
CARLSBAD, Calif., September 04, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization, compared to placebo. Consistent with previous studies, subst
Novartis’ Pelacarsen Phase III Lp(a)HORIZON Trial Fails Primary Cardiovascular Endpoint; Lowered Lp(a) Levels But Did Not Reduce CV Events
Novartis today announced that the pelacarsen phase III Lp(a)HORIZON trial, a pioneering cardiovascular outcomes study, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Ionis Pharmaceuticals wins regulatory clearance for its quarterly injection, Zanvastro, in Alexander disease. Analysts are focused elsewhere.
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals (NASDAQ:IONS) said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene. The approval includes a bro
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease Transcript
Ionis Pharmaceuticals, Inc. (IONS) Discusses FDA Approval and Launch Strategy for ZANVASTRO in Alexander Disease September 4, 2026 10:00 AM EDTCompany...
IONS Secures FDA Nod for Rare Brain Disorder Drug Zanvastro
Ionis' FDA approval of Zanvastro marks the first disease-modifying treatment for Alexander disease and adds a priority review voucher.
Ionis: Downgrading To Sell After A Series Of Unfortunate Events
Ionis Pharmaceuticals, Inc. faces significant setbacks after initial optimism, with shares dropping sharply from 52-week highs. Read more on IONS stock here.
Ionis Drug Wins FDA Approval as First Alexander Disease Treatment
The U.S. Food and Drug Administration has approved Zanvastro (zilganersen), manufactured by Ionis Pharmaceuticals Inc. (NASDAQ:IONS), for Alexander disease in adult and pediatric patients. Zanvastro becomes the first and only disease-modifying therapy available for this ultra-rare, progressive, and frequently fatal neurological disorder. Prior to this regulatory authorization, clinical care for affected individuals remained strictly limited to symptom management. First Approved Disease-Modifying
Needham Reiterates Buy on Ionis Pharmaceuticals, Maintains $86 Price Target
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $86 price target.
Why Did Ionis Pharmaceuticals (IONS) Stock Drop After Its Latest Update?
Ionis Pharmaceuticals (IONS) just received U.S. FDA approval for ZANVASTRO, an RNA targeted treatment for Alexander disease in pediatric and adult patients. The stock now reflects a new approved rare disease asset. Even with the FDA approval for ZANVASTRO, Ionis Pharmaceuticals shares have been under pressure in the near term, with the 1-day share price return down 5.22% and the 7-day share price return down 6.89%. The 30-day share price return is up 5.56% from a weaker base, and the...
BMO Capital Maintains Market Perform on Ionis Pharmaceuticals, Raises Price Target to $61
BMO Capital analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and raises the price target from $60 to $61.
Ionis Pharmaceuticals Exec Says Zanvastro Will Be Available At List Price Of $285K Per Dose
https://ir.ionis.com/events/event-details/zanvastrotm-zilganersen-fda-approval-webcas
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
HC Wainwright & Co. Reiterates Buy on Ionis Pharmaceuticals, Maintains $115 Price Target
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $115 price target.
Ionis Pharmaceuticals (IONS) Gains First-Mover Advantage with FDA Approval of Rare Brain Disease Drug
The U.S. FDA has approved Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)’s Zanvastro (zilganersen) as the first FDA-approved treatment for Alexander disease (AxD), a rare, progressive neurological disorder caused by mutations in the GFAP gene. The disease affects fewer than 1,000 people in the U.S. and can lead to seizures, loss of developmental milestones, impaired movement, and other […]
IONS Edges Up After-Hours On FDA’s Green Light For Neurology Drug After Being Dragged Down By Ultragenyx’s Failed Trial
Zanvastro is now approved for children and adults with Alexander disease, a rare and often fatal brain condition that affects fewer than one in a million people.
FDA Approves Zanvastro For Treatment Of Alexander Disease
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease
Ionis to present at upcoming investor conferences
CARLSBAD, Calif., September 03, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-31 | Birchler Brian | +58 | $51.306 | $2,976 |
| 2026-08-31 | O'NEIL PATRICK R. | +63 | $51.306 | $3,232 |
| 2026-08-31 | Monia Brett P | +98 | $51.306 | $5,028 |
| 2026-08-31 | BENNETT C FRANK | +110 | $51.306 | $5,644 |
| 2026-07-31 | Hayden Michael R | +5,000 | $51.6 | $258,000 |
| 2026-07-30 | Hayden Michael R | +15,000 | $53.38 | $800,700 |
| 2026-07-15 | Reikes Peter N | +3,399 | - | - |
| 2026-07-15 | HANTSON LUDWIG | +3,399 | - | - |
| 2026-07-15 | HERMAN JOAN E | -5,220 | - | - |
| 2026-07-15 | HERMAN JOAN E | +5,220 | - | - |
| 2026-07-15 | BERTHELSEN SPENCER R | -5,220 | - | - |
| 2026-07-15 | BERTHELSEN SPENCER R | +5,220 | - | - |
| 2026-07-07 | Kordasiewicz Holly B. | -362 | $84.3 | $30,517 |
| 2026-07-07 | Diaz Allene M. | -10,111 | - | - |
| 2026-07-07 | Diaz Allene M. | -10,111 | $85.4156 | $863,637 |
| 2026-07-07 | Diaz Allene M. | +10,111 | $47.11 | $476,329 |
| 2026-07-07 | BENNETT C FRANK | -15,000 | - | - |
| 2026-07-07 | BENNETT C FRANK | -15,000 | $85.462 | $1,281,930 |
| 2026-07-07 | BENNETT C FRANK | +15,000 | - | - |
| 2026-07-07 | BENNETT C FRANK | -5,536 | $83.579 | $462,693 |
| 2026-07-01 | Diaz Allene M. | +2,301 | - | - |
| 2026-07-01 | Diaz Allene M. | +5,369 | - | - |
| 2026-07-01 | YANG MICHAEL J. | +2,301 | - | - |
| 2026-07-01 | YANG MICHAEL J. | +5,369 | - | - |
| 2026-07-01 | Hayden Michael R | +2,301 | - | - |
| 2026-07-01 | Hayden Michael R | +5,369 | - | - |
| 2026-07-01 | LOSCALZO JOSEPH | +2,301 | - | - |
| 2026-07-01 | LOSCALZO JOSEPH | +5,369 | - | - |
| 2026-07-01 | HERMAN JOAN E | +2,301 | - | - |
| 2026-07-01 | HERMAN JOAN E | +5,369 | - | - |
| 2026-07-01 | KLEIN JOSEPH III | +2,301 | - | - |
| 2026-07-01 | KLEIN JOSEPH III | +5,369 | - | - |
| 2026-07-01 | KLEIN JOSEPH III | -11,518 | - | - |
| 2026-07-01 | KLEIN JOSEPH III | -11,419 | $79.0394 | $902,551 |
| 2026-07-01 | KLEIN JOSEPH III | -99 | $79.45 | $7,866 |
| 2026-07-01 | KLEIN JOSEPH III | +11,518 | $39.94 | $460,029 |
| 2026-07-01 | BERTHELSEN SPENCER R | +2,301 | - | - |
| 2026-07-01 | BERTHELSEN SPENCER R | +5,369 | - | - |
| 2026-06-26 | Monia Brett P | -50,000 | - | - |
| 2026-06-26 | Monia Brett P | -50,000 | $80.59 | $4,029,500 |
| 2026-06-26 | Monia Brett P | +50,000 | $56.78 | $2,839,000 |
| 2026-06-25 | Swayze Eric | -10,602 | $79.1824 | $839,492 |
| 2026-06-25 | Monia Brett P | -21,072 | - | - |
| 2026-06-25 | Monia Brett P | -21,072 | $78.49 | $1,653,941 |
| 2026-06-25 | Monia Brett P | +21,072 | $32.6 | $686,947 |
| 2026-06-24 | Monia Brett P | -14,565 | - | - |
| 2026-06-24 | Monia Brett P | -14,565 | $78.4128 | $1,142,082 |
| 2026-06-24 | Monia Brett P | +14,565 | $32.6 | $474,819 |
| 2026-06-15 | BERTHELSEN SPENCER R | -8,000 | - | - |
| 2026-06-15 | BERTHELSEN SPENCER R | -8,000 | $73.49 | $587,920 |
| 2026-06-15 | BERTHELSEN SPENCER R | +8,000 | $24.42 | $195,360 |
| 2026-06-12 | Kordasiewicz Holly B. | -21,000 | - | - |
| 2026-06-12 | Kordasiewicz Holly B. | -7,951 | - | - |
| 2026-06-12 | Kordasiewicz Holly B. | -19,895 | - | - |
| 2026-06-12 | Kordasiewicz Holly B. | -12,000 | - | - |
| 2026-06-12 | Kordasiewicz Holly B. | -19,842 | $74.0503 | $1,469,306 |
| 2026-06-12 | Kordasiewicz Holly B. | -41,004 | $73.0934 | $2,997,122 |
| 2026-06-12 | Kordasiewicz Holly B. | +19,895 | $56.78 | $1,129,638 |
| 2026-06-12 | Kordasiewicz Holly B. | +12,000 | $32.6 | $391,200 |
| 2026-06-12 | Kordasiewicz Holly B. | +21,000 | $60.89 | $1,278,690 |
| 2026-06-12 | Kordasiewicz Holly B. | +7,951 | $60.89 | $484,136 |
| 2026-06-04 | Reikes Peter N | +10,753 | - | - |
| 2026-06-04 | HANTSON LUDWIG | +10,753 | - | - |
| 2026-06-01 | BERTHELSEN SPENCER R | -8,000 | - | - |
| 2026-06-01 | BERTHELSEN SPENCER R | -8,000 | $75.67 | $605,360 |
| 2026-06-01 | BERTHELSEN SPENCER R | +8,000 | $24.42 | $195,360 |
| 2026-05-14 | Monia Brett P | -3,220 | - | - |
| 2026-05-14 | Monia Brett P | -3,220 | $78.6793 | $253,347 |
| 2026-05-14 | Monia Brett P | +3,220 | $32.6 | $104,972 |
| 2026-05-13 | Monia Brett P | -1,316 | - | - |
| 2026-05-13 | Monia Brett P | -1,316 | $78.013 | $102,665 |
| 2026-05-13 | Monia Brett P | +1,316 | $32.6 | $42,902 |
| 2026-05-04 | LOSCALZO JOSEPH | -16,000 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -12,000 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -16,000 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -10,321 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -12,000 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -10,968 | - | - |
| 2026-05-04 | LOSCALZO JOSEPH | -17,781 | $75.5826 | $1,343,934 |
| 2026-05-04 | LOSCALZO JOSEPH | -59,508 | $74.9024 | $4,457,292 |
| 2026-05-04 | LOSCALZO JOSEPH | +16,000 | $64.8 | $1,036,800 |
| 2026-05-04 | LOSCALZO JOSEPH | +12,000 | $60.2 | $722,400 |
| 2026-05-04 | LOSCALZO JOSEPH | +16,000 | $42.88 | $686,080 |
| 2026-05-04 | LOSCALZO JOSEPH | +10,321 | $41.08 | $423,987 |
| 2026-05-04 | LOSCALZO JOSEPH | +12,000 | $40.05 | $480,600 |
| 2026-05-04 | LOSCALZO JOSEPH | +10,968 | $38.06 | $417,442 |
| 2026-05-01 | KLEIN JOSEPH III | -10,111 | - | - |
| 2026-05-01 | KLEIN JOSEPH III | -1,431 | $74.4474 | $106,534 |
| 2026-05-01 | KLEIN JOSEPH III | -8,680 | $73.353 | $636,704 |
| 2026-05-01 | KLEIN JOSEPH III | +10,111 | $47.11 | $476,329 |
| 2026-04-28 | Baroldi Joseph | -1,626 | $71.7877 | $116,727 |
| 2026-04-16 | Birchler Brian | -973 | $75.042 | $73,016 |
| 2026-04-16 | Baroldi Joseph | -5,619 | $74.56 | $418,953 |
| 2026-04-16 | Jenne Kyle | -4,902 | $75.171 | $368,488 |
| 2026-04-15 | Birchler Brian | -1,875 | - | - |
| 2026-04-15 | Birchler Brian | +1,875 | - | - |
| 2026-04-15 | Baroldi Joseph | -10,837 | - | - |
| 2026-04-15 | Baroldi Joseph | +10,837 | - | - |
| 2026-04-15 | Jenne Kyle | -12,226 | - | - |
| 2026-04-15 | Jenne Kyle | +12,226 | - | - |
| 2026-04-15 | PARSHALL B LYNNE | -534 | $76.97 | $41,102 |
| 2026-04-15 | PARSHALL B LYNNE | -4,466 | $76.19 | $340,265 |
| 2026-04-02 | Devers Shannon L. | -6,193 | $74.0535 | $458,613 |
| 2026-04-01 | KLEIN JOSEPH III | -10,321 | - | - |
| 2026-04-01 | KLEIN JOSEPH III | -12,000 | - | - |
| 2026-04-01 | KLEIN JOSEPH III | -2,216 | $75.954 | $168,314 |
| 2026-04-01 | KLEIN JOSEPH III | -20,105 | $75.503 | $1,517,988 |
| 2026-04-01 | KLEIN JOSEPH III | +10,321 | $41.08 | $423,987 |
| 2026-04-01 | KLEIN JOSEPH III | +12,000 | $38.06 | $456,720 |
| 2026-03-19 | Schneider Eugene | -5,812 | $70.9715 | $412,486 |
| 2026-03-17 | HOUGEN ELIZABETH L | -10,172 | $73.207 | $744,662 |
| 2026-03-16 | HOUGEN ELIZABETH L | -60,299 | - | - |
| 2026-03-16 | HOUGEN ELIZABETH L | -61,041 | - | - |
| 2026-03-16 | HOUGEN ELIZABETH L | -20,541 | - | - |
| 2026-03-16 | HOUGEN ELIZABETH L | -33,118 | - | - |
| 2026-03-16 | HOUGEN ELIZABETH L | -9,440 | $72.765 | $686,902 |
| 2026-03-16 | HOUGEN ELIZABETH L | -205,608 | $72.381 | $14,882,113 |
| 2026-03-16 | HOUGEN ELIZABETH L | +20,541 | $37.58 | $771,931 |
| 2026-03-16 | HOUGEN ELIZABETH L | +33,118 | $32.6 | $1,079,647 |
| 2026-03-16 | HOUGEN ELIZABETH L | +61,041 | $56.78 | $3,465,908 |
| 2026-03-16 | HOUGEN ELIZABETH L | +60,299 | $60.89 | $3,671,606 |
| 2026-03-10 | Jenne Kyle | -32,602 | - | - |
| 2026-03-10 | Jenne Kyle | -4,675 | - | - |
| 2026-03-10 | Jenne Kyle | +4,675 | $34.69 | $162,176 |
| 2026-03-10 | Jenne Kyle | -16,086 | $76.3 | $1,227,362 |
| 2026-03-10 | Jenne Kyle | -21,191 | $75.502 | $1,599,963 |
| 2026-03-10 | Jenne Kyle | +32,602 | $46.1 | $1,502,952 |
| 2026-03-10 | Monia Brett P | -34,103 | - | - |
| 2026-03-10 | Monia Brett P | -17,591 | $76.3407 | $1,342,909 |
| 2026-03-10 | Monia Brett P | -16,512 | $75.4745 | $1,246,235 |
| 2026-03-10 | Monia Brett P | +34,103 | $60.89 | $2,076,532 |
| 2026-03-09 | O'NEIL PATRICK R. | -10,148 | $75.2525 | $763,662 |
| 2026-03-09 | Monia Brett P | -73,529 | - | - |
| 2026-03-09 | Monia Brett P | -40,822 | - | - |
| 2026-03-09 | Monia Brett P | -1,684 | $75.583 | $127,282 |
| 2026-03-09 | Monia Brett P | -117,604 | $75.258 | $8,850,642 |
| 2026-03-09 | Monia Brett P | -7,382 | $74.111 | $547,087 |
| 2026-03-09 | Monia Brett P | +73,529 | $60.89 | $4,477,181 |
| 2026-03-09 | Monia Brett P | +40,822 | $60.89 | $2,485,652 |
| 2026-03-04 | Baroldi Joseph | -238 | - | - |
| 2026-03-04 | Baroldi Joseph | -201 | - | - |
| 2026-03-04 | Baroldi Joseph | -201 | $80 | $16,080 |
| 2026-03-04 | Baroldi Joseph | +201 | $32.6 | $6,553 |
| 2026-03-04 | Baroldi Joseph | -238 | $80 | $19,040 |
| 2026-03-04 | Baroldi Joseph | +238 | $56.78 | $13,514 |
| 2026-03-04 | LOSCALZO JOSEPH | -200 | - | - |
| 2026-03-04 | LOSCALZO JOSEPH | -200 | $80 | $16,000 |
| 2026-03-04 | LOSCALZO JOSEPH | +200 | $38.06 | $7,612 |
| 2026-03-03 | Devers Shannon L. | -385 | - | - |
| 2026-03-03 | Devers Shannon L. | -3,760 | - | - |
| 2026-03-03 | Devers Shannon L. | -3,510 | - | - |
| 2026-03-03 | Devers Shannon L. | -5,500 | - | - |
| 2026-03-03 | Devers Shannon L. | -6,951 | - | - |
| 2026-03-03 | Devers Shannon L. | -755 | $80.837 | $61,032 |
| 2026-03-03 | Devers Shannon L. | -5,030 | $79.999 | $402,395 |
| 2026-03-03 | Devers Shannon L. | -14,321 | $79.115 | $1,133,006 |
| 2026-03-03 | Devers Shannon L. | +385 | $52.87 | $20,355 |
| 2026-03-03 | Devers Shannon L. | +6,951 | $32.6 | $226,603 |
| 2026-03-03 | Devers Shannon L. | +5,500 | $34.69 | $190,795 |
| 2026-03-03 | Devers Shannon L. | +3,760 | $40.85 | $153,596 |
| 2026-03-03 | Devers Shannon L. | +3,510 | $37.58 | $131,906 |
| 2026-03-03 | Baroldi Joseph | -820 | - | - |
| 2026-03-03 | Baroldi Joseph | -879 | - | - |
| 2026-03-03 | Baroldi Joseph | -36 | $81.01 | $2,916 |
| 2026-03-03 | Baroldi Joseph | -2,088 | $80.4079 | $167,892 |
| 2026-03-03 | Baroldi Joseph | +879 | $32.6 | $28,655 |
| 2026-03-03 | Baroldi Joseph | +820 | $56.78 | $46,560 |
| 2026-03-03 | Baroldi Joseph | -4,096 | $79.36 | $325,059 |
| 2026-03-03 | Diaz Allene M. | -10,321 | - | - |
| 2026-03-03 | Diaz Allene M. | -18,000 | - | - |
| 2026-03-03 | Diaz Allene M. | -12,000 | - | - |
| 2026-03-03 | Diaz Allene M. | -1,005 | $80.799 | $81,203 |
| 2026-03-03 | Diaz Allene M. | -14,608 | $79.875 | $1,166,814 |
| 2026-03-03 | Diaz Allene M. | -39,265 | $79.114 | $3,106,411 |
| 2026-03-03 | Diaz Allene M. | +18,000 | $40.05 | $720,900 |
| 2026-03-03 | Diaz Allene M. | +12,000 | $38.06 | $456,720 |
| 2026-03-03 | Diaz Allene M. | +10,321 | $41.08 | $423,987 |
| 2026-03-03 | LOSCALZO JOSEPH | -832 | - | - |
| 2026-03-03 | LOSCALZO JOSEPH | -832 | $80.3279 | $66,833 |
| 2026-03-03 | LOSCALZO JOSEPH | +832 | $38.06 | $31,666 |
| 2026-03-03 | KLEIN JOSEPH III | -4,000 | - | - |
| 2026-03-03 | KLEIN JOSEPH III | -12,000 | - | - |
| 2026-03-03 | KLEIN JOSEPH III | -1,012 | $80.818 | $81,788 |
| 2026-03-03 | KLEIN JOSEPH III | -6,794 | $79.995 | $543,486 |
| 2026-03-03 | KLEIN JOSEPH III | -13,526 | $79.174 | $1,070,908 |
| 2026-03-03 | KLEIN JOSEPH III | +4,000 | $42.88 | $171,520 |
| 2026-03-03 | KLEIN JOSEPH III | +12,000 | $40.05 | $480,600 |
| 2026-03-03 | BENNETT C FRANK | -48,626 | - | - |
| 2026-03-03 | BENNETT C FRANK | -16,463 | - | - |
| 2026-03-03 | BENNETT C FRANK | -802 | $80.762 | $64,771 |
| 2026-03-03 | BENNETT C FRANK | -12,687 | $79.8778 | $1,013,410 |
| 2026-03-03 | BENNETT C FRANK | -71,600 | $79.099 | $5,663,488 |
| 2026-03-03 | BENNETT C FRANK | +48,626 | $60.89 | $2,960,837 |
| 2026-03-03 | BENNETT C FRANK | +16,463 | $32.6 | $536,694 |
| 2026-02-27 | Birchler Brian | +351 | $48.8665 | $17,152 |
| 2026-02-27 | Swayze Eric | +256 | $48.8665 | $12,510 |
| 2026-02-27 | O'NEIL PATRICK R. | +376 | $48.8665 | $18,374 |
| 2026-02-27 | Monia Brett P | +484 | $48.8665 | $23,651 |
| 2026-02-27 | BENNETT C FRANK | +261 | $48.8665 | $12,754 |
| 2026-02-13 | Swayze Eric | -6,207 | $82.0691 | $509,403 |
| 2026-02-13 | Swayze Eric | -9,435 | $81.5592 | $769,511 |
| 2026-02-11 | PARSHALL B LYNNE | -5,000 | $82.7177 | $413,588 |
| 2026-02-06 | Monia Brett P | -29,430 | $85.7907 | $2,524,820 |
| 2026-02-02 | BENNETT C FRANK | 0 | - | - |
| 2026-02-02 | BENNETT C FRANK | -48,626 | - | - |
| 2026-02-02 | BENNETT C FRANK | -16,463 | - | - |
| 2026-02-02 | BENNETT C FRANK | -16,463 | $83.0284 | $1,366,897 |
| 2026-02-02 | BENNETT C FRANK | +16,463 | $32.6 | $536,694 |
| 2026-02-02 | BENNETT C FRANK | -48,626 | $83.0284 | $4,037,339 |
| 2026-02-02 | BENNETT C FRANK | +48,626 | $60.89 | $2,960,837 |
| 2026-02-02 | BENNETT C FRANK | -20,000 | $82.599 | $1,651,980 |
| 2026-01-30 | Birchler Brian | -6,179 | $83.0309 | $513,048 |
| 2026-01-30 | Schneider Eugene | -6,179 | $83.4487 | $515,630 |
| 2026-01-30 | Baroldi Joseph | -5,296 | $82.9615 | $439,364 |
| 2026-01-30 | Swayze Eric | -6,179 | $82.9335 | $512,446 |
| 2026-01-30 | O'NEIL PATRICK R. | -6,179 | $83.5335 | $516,153 |
| 2026-01-30 | Monia Brett P | -62,970 | $82.7216 | $5,208,979 |
| 2026-01-30 | HOUGEN ELIZABETH L | -6,988 | $83.243 | $581,702 |
| 2026-01-30 | BENNETT C FRANK | -5,885 | $82.9466 | $488,141 |
| 2026-01-29 | Birchler Brian | +11,991 | - | - |
| 2026-01-29 | Schneider Eugene | +11,991 | - | - |
| 2026-01-29 | Baroldi Joseph | +10,278 | - | - |
| 2026-01-29 | Swayze Eric | +11,991 | - | - |
| 2026-01-29 | O'NEIL PATRICK R. | +11,991 | - | - |
| 2026-01-29 | Monia Brett P | +122,214 | - | - |
| 2026-01-29 | HOUGEN ELIZABETH L | +13,562 | - | - |
| 2026-01-29 | BENNETT C FRANK | +11,421 | - | - |
| 2026-01-22 | Devers Shannon L. | -3,977 | $81.3403 | $323,490 |
| 2026-01-16 | Kordasiewicz Holly B. | -4,141 | $75.66 | $313,308 |
| 2026-01-16 | Devers Shannon L. | -8,353 | $75.95 | $634,410 |
| 2026-01-16 | Birchler Brian | -8,480 | $75.11 | $636,933 |
| 2026-01-16 | Schneider Eugene | -9,302 | $75.59 | $703,138 |
| 2026-01-16 | Baroldi Joseph | -1,149 | $75.78 | $87,071 |
| 2026-01-16 | Baroldi Joseph | -6,907 | $75.75 | $523,205 |
| 2026-01-16 | Jenne Kyle | -1,823 | $75.96 | $138,475 |
| 2026-01-16 | Swayze Eric | -49 | $75.97 | $3,723 |
| 2026-01-16 | Swayze Eric | -9,884 | $75.34 | $744,661 |
| 2026-01-16 | O'NEIL PATRICK R. | -9,191 | $75.84 | $697,045 |
| 2026-01-16 | Monia Brett P | -44,034 | $74.82 | $3,294,624 |
| 2026-01-16 | HOUGEN ELIZABETH L | -12,922 | $75.22 | $971,993 |
| 2026-01-16 | BENNETT C FRANK | -8,977 | $75.15 | $674,622 |
| 2026-01-15 | Kordasiewicz Holly B. | +11,250 | - | - |
| 2026-01-15 | Kordasiewicz Holly B. | +13,650 | - | - |
| 2026-01-15 | Kordasiewicz Holly B. | -11,119 | - | - |
| 2026-01-15 | Kordasiewicz Holly B. | +11,119 | - | - |
| 2026-01-15 | Devers Shannon L. | +9,675 | - | - |
| 2026-01-15 | Devers Shannon L. | -17,377 | - | - |
| 2026-01-15 | Devers Shannon L. | +25,800 | - | - |
| 2026-01-15 | Devers Shannon L. | +17,377 | - | - |
| 2026-01-15 | Birchler Brian | +9,675 | - | - |
| 2026-01-15 | Birchler Brian | -20,089 | - | - |
| 2026-01-15 | Birchler Brian | +25,800 | - | - |
| 2026-01-15 | Birchler Brian | +20,089 | - | - |
| 2026-01-15 | Schneider Eugene | +9,675 | - | - |
| 2026-01-15 | Schneider Eugene | -21,685 | - | - |
| 2026-01-15 | Schneider Eugene | +25,800 | - | - |
| 2026-01-15 | Schneider Eugene | +21,685 | - | - |
| 2026-01-15 | Baroldi Joseph | +3,900 | - | - |
| 2026-01-15 | Baroldi Joseph | -2,850 | - | - |
| 2026-01-15 | Baroldi Joseph | +9,675 | - | - |
| 2026-01-15 | Baroldi Joseph | -17,037 | - | - |
| 2026-01-15 | Baroldi Joseph | +25,800 | - | - |
| 2026-01-15 | Baroldi Joseph | +2,850 | - | - |
| 2026-01-15 | Baroldi Joseph | +17,037 | - | - |
| 2026-01-15 | Jenne Kyle | -7,013 | - | - |
| 2026-01-15 | Jenne Kyle | +9,675 | - | - |
| 2026-01-15 | Jenne Kyle | +25,800 | - | - |
| 2026-01-15 | Jenne Kyle | +7,013 | - | - |
| 2026-01-15 | Swayze Eric | +225 | - | - |
| 2026-01-15 | Swayze Eric | -111 | - | - |
| 2026-01-15 | Swayze Eric | +9,675 | - | - |
| 2026-01-15 | Swayze Eric | -21,366 | - | - |
| 2026-01-15 | Swayze Eric | +25,800 | - | - |
| 2026-01-15 | Swayze Eric | +111 | - | - |
| 2026-01-15 | Swayze Eric | +21,366 | - | - |
| 2026-01-15 | YANG MICHAEL J. | -1,930 | - | - |
| 2026-01-15 | YANG MICHAEL J. | +1,930 | - | - |
| 2026-01-15 | O'NEIL PATRICK R. | +9,675 | - | - |
| 2026-01-15 | O'NEIL PATRICK R. | -21,473 | - | - |
| 2026-01-15 | O'NEIL PATRICK R. | +25,800 | - | - |
| 2026-01-15 | O'NEIL PATRICK R. | +21,473 | - | - |
| 2026-01-15 | Monia Brett P | +42,705 | - | - |
| 2026-01-15 | Monia Brett P | -89,145 | - | - |
| 2026-01-15 | Monia Brett P | +113,880 | - | - |
| 2026-01-15 | Monia Brett P | +89,145 | - | - |
| 2026-01-15 | HOUGEN ELIZABETH L | +12,885 | - | - |
| 2026-01-15 | HOUGEN ELIZABETH L | -28,729 | - | - |
| 2026-01-15 | HOUGEN ELIZABETH L | +34,360 | - | - |
| 2026-01-15 | HOUGEN ELIZABETH L | +28,729 | - | - |
| 2026-01-15 | BENNETT C FRANK | +9,675 | - | - |
| 2026-01-15 | BENNETT C FRANK | -21,055 | - | - |
| 2026-01-15 | BENNETT C FRANK | +25,800 | - | - |
| 2026-01-15 | BENNETT C FRANK | +21,055 | - | - |
| 2026-01-07 | Devers Shannon L. | -25,545 | - | - |
| 2026-01-07 | Devers Shannon L. | -9,264 | - | - |
| 2026-01-07 | Devers Shannon L. | -3,829 | - | - |
| 2026-01-07 | Devers Shannon L. | -3,460 | - | - |
| 2026-01-07 | Devers Shannon L. | -2,101 | - | - |
| 2026-01-07 | Devers Shannon L. | -9,264 | $84.62 | $783,920 |
| 2026-01-07 | Devers Shannon L. | +9,264 | $52.87 | $489,788 |
| 2026-01-07 | Devers Shannon L. | -3,829 | $84.62 | $324,010 |
| 2026-01-07 | Devers Shannon L. | +3,829 | $37.58 | $143,894 |
| 2026-01-07 | Devers Shannon L. | -3,460 | $84.62 | $292,785 |
| 2026-01-07 | Devers Shannon L. | +3,460 | $32.6 | $112,796 |
| 2026-01-07 | Devers Shannon L. | -2,101 | $85.36 | $179,341 |
| 2026-01-07 | Devers Shannon L. | +2,101 | $32.6 | $68,493 |
| 2026-01-07 | Devers Shannon L. | -25,545 | $85.36 | $2,180,521 |
| 2026-01-07 | Devers Shannon L. | +25,545 | $56.78 | $1,450,445 |
| 2026-01-02 | Kordasiewicz Holly B. | +7,500 | - | - |
| 2026-01-02 | Schneider Eugene | +19,350 | - | - |
| 2026-01-02 | Kordasiewicz Holly B. | +9,100 | - | - |
| 2026-01-02 | Devers Shannon L. | +19,350 | - | - |
| 2026-01-02 | Birchler Brian | +19,350 | - | - |
| 2026-01-02 | Baroldi Joseph | +2,600 | - | - |
| 2026-01-02 | Baroldi Joseph | +19,350 | - | - |
| 2026-01-02 | Jenne Kyle | +19,350 | - | - |
| 2026-01-02 | Swayze Eric | +150 | - | - |
| 2026-01-02 | Swayze Eric | +19,350 | - | - |
| 2026-01-02 | Swayze Eric | -18,338 | - | - |
| 2026-01-02 | Swayze Eric | -5,125 | - | - |
| 2026-01-02 | Swayze Eric | -18,338 | $79.27 | $1,453,653 |
| 2026-01-02 | Swayze Eric | +18,338 | $60.89 | $1,116,601 |
| 2026-01-02 | Swayze Eric | -5,125 | $78.57 | $402,671 |
| 2026-01-02 | Swayze Eric | +5,125 | $60.89 | $312,061 |
| 2026-01-02 | O'NEIL PATRICK R. | +19,350 | - | - |
| 2026-01-02 | Monia Brett P | +85,410 | - | - |
| 2026-01-02 | HOUGEN ELIZABETH L | +25,770 | - | - |
| 2026-01-02 | BENNETT C FRANK | +19,350 | - | - |
| 2025-12-01 | WENDER JOSEPH H | -7,429 | $81.2338 | $603,486 |
| 2025-12-01 | WENDER JOSEPH H | -20,571 | $80.6651 | $1,659,362 |
| 2025-11-25 | Devers Shannon L. | -16,777 | - | - |
| 2025-11-25 | Devers Shannon L. | -16,777 | $80.9109 | $1,357,442 |
| 2025-11-25 | Devers Shannon L. | +16,777 | $53.77 | $902,099 |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | - | - |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | - | - |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | - | - |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | $80 | $320,000 |
| 2025-11-25 | KLEIN JOSEPH III | +4,000 | - | - |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | $80 | $320,000 |
| 2025-11-25 | KLEIN JOSEPH III | +4,000 | - | - |
| 2025-11-25 | KLEIN JOSEPH III | -4,000 | $80 | $320,000 |
| 2025-11-25 | KLEIN JOSEPH III | +4,000 | - | - |
| 2025-11-19 | HERMAN JOAN E | -32,000 | - | - |
| 2025-11-19 | HERMAN JOAN E | -12,000 | - | - |
| 2025-11-19 | HERMAN JOAN E | -32,000 | $72.1325 | $2,308,240 |
| 2025-11-19 | HERMAN JOAN E | +32,000 | $63.9 | $2,044,800 |
| 2025-11-19 | HERMAN JOAN E | -12,000 | $72.1325 | $865,590 |
| 2025-11-19 | HERMAN JOAN E | +12,000 | $40.05 | $480,600 |
| 2025-11-18 | WENDER JOSEPH H | -16,000 | - | - |
| 2025-11-18 | WENDER JOSEPH H | +16,000 | $24.42 | $390,720 |
| 2025-11-06 | Birchler Brian | -8,000 | $76.1724 | $609,379 |
| 2025-11-06 | Geary Richard S | -18,300 | - | - |
| 2025-11-06 | Geary Richard S | -14,738 | - | - |
| 2025-11-06 | Geary Richard S | -18,300 | $75.421 | $1,380,204 |
| 2025-11-06 | Geary Richard S | +18,300 | $60.89 | $1,114,287 |
| 2025-11-06 | Geary Richard S | -14,738 | $76.0972 | $1,121,521 |
| 2025-11-06 | Geary Richard S | +14,738 | $56.78 | $836,824 |
| 2025-11-05 | Geary Richard S | -801 | - | - |
| 2025-11-05 | Geary Richard S | -800 | - | - |
| 2025-11-05 | Geary Richard S | -801 | $75.01 | $60,083 |
| 2025-11-05 | Geary Richard S | +801 | $60.89 | $48,773 |
| 2025-11-05 | Geary Richard S | -800 | $75.01 | $60,008 |
| 2025-11-05 | Geary Richard S | +800 | $56.78 | $45,424 |
| 2025-11-03 | Geary Richard S | -775 | - | - |
| 2025-11-03 | Geary Richard S | -905 | - | - |
| 2025-11-03 | Geary Richard S | -905 | $75.054 | $67,924 |
| 2025-11-03 | Geary Richard S | +905 | $56.78 | $51,386 |
| 2025-11-03 | Geary Richard S | -775 | $75.054 | $58,167 |
| 2025-11-03 | Geary Richard S | +775 | $60.89 | $47,190 |
| 2025-11-03 | Geary Richard S | -905 | - | - |
| 2025-11-03 | Geary Richard S | -775 | - | - |
| 2025-11-03 | Geary Richard S | -905 | $75.054 | $67,924 |
| 2025-11-03 | Geary Richard S | +905 | $60.89 | $55,105 |
| 2025-11-03 | Geary Richard S | -775 | $75.054 | $58,167 |
| 2025-11-03 | Geary Richard S | +775 | $56.78 | $44,005 |
| 2025-10-31 | Geary Richard S | -34,585 | - | - |
| 2025-10-31 | Geary Richard S | -34,664 | - | - |
| 2025-10-31 | Geary Richard S | -20,000 | $75.1083 | $1,502,166 |
| 2025-10-31 | Geary Richard S | -34,664 | $75.1083 | $2,603,554 |
| 2025-10-31 | Geary Richard S | +34,664 | $56.78 | $1,968,222 |
| 2025-10-31 | Geary Richard S | -34,585 | $75.1083 | $2,597,621 |
| 2025-10-31 | Geary Richard S | +34,585 | $60.89 | $2,105,881 |
| 2025-10-31 | LOSCALZO JOSEPH | -16,000 | - | - |
| 2025-10-31 | LOSCALZO JOSEPH | -16,000 | $75.1043 | $1,201,669 |
| 2025-10-31 | LOSCALZO JOSEPH | +16,000 | $52.22 | $835,520 |
| 2025-10-31 | WENDER JOSEPH H | -11,200 | $75.1586 | $841,776 |
| 2025-10-30 | WENDER JOSEPH H | -5,975 | $73.85 | $441,254 |
| 2025-10-30 | WENDER JOSEPH H | -8,341 | $73.16 | $610,228 |
| 2025-10-30 | WENDER JOSEPH H | -2,484 | $72.19 | $179,320 |
| 2025-10-16 | Devers Shannon L. | -1,263 | $73.6213 | $92,984 |
| 2025-10-16 | Swayze Eric | -53 | $73.6213 | $3,902 |
| 2025-10-15 | Devers Shannon L. | -2,820 | - | - |
| 2025-10-15 | Devers Shannon L. | -6,000 | - | - |
| 2025-10-15 | Devers Shannon L. | +2,820 | - | - |
| 2025-10-15 | Devers Shannon L. | -6,000 | $72.9423 | $437,654 |
| 2025-10-15 | Devers Shannon L. | +6,000 | $48.51 | $291,060 |
| 2025-10-15 | Birchler Brian | -12,425 | - | - |
| 2025-10-15 | Birchler Brian | -12,425 | $72.2252 | $897,398 |
| 2025-10-15 | Birchler Brian | +12,425 | $53.77 | $668,092 |
| 2025-10-15 | Swayze Eric | -125 | - | - |
| 2025-10-15 | Swayze Eric | +125 | - | - |
| 2025-10-15 | PARSHALL B LYNNE | -5,000 | $71.7443 | $358,722 |
| 2025-10-14 | Birchler Brian | -11,475 | - | - |
| 2025-10-14 | Birchler Brian | -11,475 | $72.0339 | $826,589 |
| 2025-10-14 | Birchler Brian | +11,475 | $53.77 | $617,011 |
| 2025-10-06 | Baroldi Joseph | -1,625 | $69.3693 | $112,725 |
| 2025-10-06 | Swayze Eric | -6,849 | $69.02 | $472,718 |
| 2025-10-06 | O'NEIL PATRICK R. | -10,200 | - | - |
| 2025-10-06 | O'NEIL PATRICK R. | -3,241 | $69.2651 | $224,488 |
| 2025-10-06 | O'NEIL PATRICK R. | -10,200 | $69.8872 | $712,849 |
| 2025-10-06 | O'NEIL PATRICK R. | +10,200 | $52.87 | $539,274 |
| 2025-10-06 | Monia Brett P | -437 | $69.2637 | $30,268 |